Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study
- PMID: 37653457
- PMCID: PMC10472555
- DOI: 10.1186/s40662-023-00354-1
Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study
Erratum in
-
Correction: Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study.Eye Vis (Lond). 2023 Sep 25;10(1):41. doi: 10.1186/s40662-023-00360-3. Eye Vis (Lond). 2023. PMID: 37743491 Free PMC article. No abstract available.
Abstract
Background: This study aimed to compare the complication rates of epithelium-off corneal cross-linking (epi-off CXL) performed in an office-based setting with those of epi-off CXL performed in an operating room.
Methods: A retrospective cohort study, comprising 501 consecutive epi-off CXL procedures, performed in a non-sterile procedure room without laminar flow ventilation at the ELZA Institute in Zurich, Switzerland, between November 2015 and October 2021, was conducted.
Results: No cases of postoperative infectious keratitis were observed, while sterile infiltrates occurred in 10 out of 501 (2.00%) patients, all of whom responded well to topical steroid therapy. Delayed epithelialization (> 7 days) occurred in 14 out of 501 (2.79%) patients. No other adverse events were noted.
Conclusions: Office-based epi-off CXL does not appear to be associated with an increased risk of complications when compared to operating room settings.
Keywords: Cornea; Corneal cross-linking; Epithelium-off; Infectious keratitis; Keratoconus; Office-based; Slit lamp; Sterile infiltrates.
© 2023. The Author(s).
Conflict of interest statement
NH is CEO of EMAGine AG, a company producing a CXL device. FH holds a patent on a UV light source (PCT/CH 2012/000090) and is CSO of EMAGine AG. FH is an editorial board member of Eye and Vision. The other authors have no proprietary or commercial interest in any of the materials discussed in this article.
References
-
- Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21. - PubMed
LinkOut - more resources
Full Text Sources
